Ankylosing Spondylitis

Immunology
21
Pipeline Programs
14
Companies
50
Clinical Trials
2 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
6
0
8
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1173%
Small Molecule
427%
+ 7 programs with unclassified modality

On Market (4)

Approved therapies currently available

UP
BIMZELXApproved
bimekizumab
UCB Pharma
injection2023
U
ENBRELApproved
etanercept
Unknown Company
Tumor Necrosis Factor Blocker [EPC]subcutaneous1998
U
REMICADEApproved
infliximab
Unknown Company
Tumor Necrosis Factor Blocker [EPC]intravenous1998
U
SIMPONIApproved
golimumab
Unknown Company
Tumor Necrosis Factor Blocker [EPC]injection2009

Competitive Landscape

13 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
3 programs
2
1
1
BimekizumabPhase 3Monoclonal Antibody1 trial
BimekizumabPhase 2Monoclonal Antibody1 trial
BimekizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03215277Completed76Est. May 2020
NCT03355573Completed255Est. Oct 2022
NCT03928743Completed332Est. Aug 2022
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
GolimumabPhase 4Monoclonal Antibody1 trial
InfliximabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00844805Completed158Est. Sep 2011
NCT01668004Completed101Est. Apr 2015
Pfizer
PfizerNEW YORK, NY
3 programs
1
EtanerceptPhase 35 trials
Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing SpondylitisN/A1 trial
Treatment switchingN/A1 trial
Active Trials
NCT00227227Completed750Est. Jun 2007
NCT00900796CompletedEst. May 2011
NCT00063869Completed88Est. Mar 2005
+4 more trials
Galapagos
Galapagos2800 MECHELEN, Belgium
3 programs
1
2
FilgotinibPhase 3Small Molecule
FilgotinibPhase 3Small Molecule
filgotinibPhase 2Small Molecule1 trial
Active Trials
NCT03117270Completed116Est. Jul 2018
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
FilgotinibPhase 3Small Molecule1 trial
Active Trials
NCT04483687Withdrawn0Est. Sep 2024
E
EisaiChina - Liaoning
1 program
1
adalimumabPhase 3Monoclonal Antibody
Abbott
AbbottABBOTT PARK, IL
1 program
1
adalimumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00478660Completed1,250
Affibody
AffibodySweden - Solna
1 program
1
ABY-035Phase 21 trial
Active Trials
NCT04795141TerminatedEst. Aug 2022
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
SarilumabPhase 2Monoclonal Antibody
Sanofi
SanofiPARIS, France
1 program
1
drug treatmentPhase 21 trial
Active Trials
NCT01038011CompletedEst. Aug 2006
Celltrion
CelltrionKorea - Incheon
2 programs
2
InfliximabPhase 1Monoclonal Antibody1 trial
InfliximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT01220518Completed257Est. Jun 2012
NCT01571206Completed174Est. May 2013
Novartis
NovartisBASEL, Switzerland
2 programs
PhysiotherapyN/A1 trial
SecukinumabN/AMonoclonal Antibody1 trial
Active Trials
NCT03457285Unknown20Est. May 2019
NCT06905288Recruiting70Est. Dec 2026
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)N/A1 trial
Active Trials
NCT01329380Completed403Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerEtanercept
Merck & Co.Golimumab
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept
PfizerEtanercept

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 10,823 patients across 50 trials

Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA

Start: Sep 2015Est. completion: Sep 2019210 patients
Phase 4Completed

The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)

Start: Sep 2012Est. completion: Apr 2015101 patients
Phase 4Completed

Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept

Start: Jan 2010Est. completion: Apr 2013174 patients
Phase 4Completed

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

Start: Sep 2009Est. completion: Dec 2012306 patients
Phase 4Completed

Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

Start: Jul 2009Est. completion: Apr 201160 patients
Phase 4Completed

Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients

Start: Oct 2008Est. completion: Apr 2010108 patients
Phase 4Completed

Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects

Start: Sep 2008Est. completion: May 2010141 patients
Phase 4Terminated

Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Start: Sep 2007Est. completion: Oct 2009136 patients
Phase 4Completed

Remission Induction in Very Early Rheumatoid Arthritis

Start: Sep 200720 patients
Phase 4Unknown

Extension Study Evaluating Etanercept in Ankylosing Spondylitis

Start: Dec 2006Est. completion: Oct 200884 patients
Phase 4Completed

Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept

Start: Feb 2006Est. completion: Aug 2007500 patients
Phase 4Completed

Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

Start: Dec 2005Est. completion: Feb 2008566 patients
Phase 4Completed

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Start: Apr 2005Est. completion: Dec 200660 patients
Phase 4Completed

Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

Start: Dec 2004Est. completion: Feb 2007720 patients
Phase 4Completed

Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects

Start: Jun 2004Est. completion: Sep 2005300 patients
Phase 4Completed

Study Evaluating the Efficacy and Safety of Etanercept

Start: Jan 2003Est. completion: Feb 200540 patients
Phase 4Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy

Start: Dec 2020Est. completion: Sep 20240
Phase 3Withdrawn

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Start: May 2019Est. completion: Feb 2025260 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Start: Apr 2019Est. completion: Aug 2022332 patients
Phase 3Completed

Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects

Start: Apr 2015Est. completion: Jun 2016188 patients
Phase 3Completed

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Start: Oct 2011Est. completion: Feb 2021109 patients
Phase 3Completed

Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)

Start: Sep 2009Est. completion: Sep 2011158 patients
Phase 3Completed

Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Start: Sep 2007Est. completion: Sep 2009640 patients
Phase 3Completed

A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis

Start: Apr 2007Est. completion: Dec 200780 patients
Phase 3Completed

Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis

Start: Feb 2007Est. completion: Jun 2007150 patients
Phase 3Completed

Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis

Start: Jul 2006Est. completion: Jul 2010550 patients
Phase 3Completed

Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis

Start: Jun 2006Est. completion: Jul 2007150 patients
Phase 3Completed

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)

Start: Feb 20061,250 patients
Phase 3Completed

Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study

Start: Feb 2005Est. completion: Nov 200634 patients
Phase 3Completed

Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis

Start: Jun 2004Est. completion: Feb 2005350 patients
Phase 3Completed

Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis

Start: Mar 2002Est. completion: Aug 200284 patients
Phase 3Completed

Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.

Start: Oct 2000Est. completion: Oct 2001615 patients
Phase 3Completed

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis

Est. completion: Mar 200588 patients
Phase 2Completed

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Start: Aug 2021Est. completion: Aug 2022
Phase 2Terminated

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Start: Nov 2017Est. completion: Oct 2022255 patients
Phase 2Completed

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Start: Oct 2017Est. completion: May 202076 patients
Phase 2Completed

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis

Start: Mar 2017Est. completion: Jul 2018116 patients
Phase 2Completed

Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus

Start: Feb 2016Est. completion: Dec 201725 patients
Phase 2Completed

Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)

Start: Nov 2005Est. completion: Jul 201380 patients
Phase 2Unknown

Study Evaluating Etanercept in Moderate to Severe Asthma

Start: May 2005Est. completion: Jul 2006120 patients
Phase 2Completed
NCT01038011Sanofidrug treatment

Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study

Start: Jun 2004Est. completion: Aug 2006
Phase 2Completed

An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1

Start: Mar 2012Est. completion: May 2013174 patients
Phase 1Completed

Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

Start: Oct 2010Est. completion: Jun 2012257 patients
Phase 1Completed

Study Evaluating Enbrel Drug Levels in Healthy Male Chinese Subjects

Start: Jul 2008Est. completion: Nov 200860 patients
Phase 1Completed

Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects

Start: Jul 2007Est. completion: Aug 2007
Phase 1Completed

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

Start: Apr 2025Est. completion: Dec 202670 patients
N/ARecruiting

A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis

Start: Jun 2024Est. completion: May 202560 patients
N/ATerminated

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Start: Sep 2020Est. completion: Oct 2020763 patients
N/ACompleted
NCT03457285NovartisPhysiotherapy

Investigating the Use of Salaso to Improve Physiotherapy Management of Ankylosing Spondylitis (AS).

Start: Oct 2018Est. completion: May 201920 patients
N/AUnknown

The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis

Start: May 2015Est. completion: Dec 2016183 patients
N/ACompleted

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 10,823 patients
Monoclonal Antibody is the dominant modality (73% of programs)
14 companies competing in this space